Zymeworks Inc. ZYME

ZYME Company Overview

Zymeworks Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of multifunctional biotherapeutics for the treatment of cancer and other serious diseases. The company operates within the biotechnology and oncology drug development industries, with a strategic emphasis on next-generation antibody-based therapeutics. Its core business centers on developing proprietary therapeutic platforms and advancing internally developed oncology candidates through clinical development while also generating revenue through licensing and collaboration agreements.

The company’s primary value drivers include its proprietary protein engineering technologies, particularly the Azymetric and EFECT platforms, which are designed to enable the creation of bispecific and multispecific antibodies with improved therapeutic functionality. Zymeworks has historically focused on HER2-targeted therapies and broader oncology applications, serving pharmaceutical partners, oncology treatment markets, and patients with difficult-to-treat cancers. Founded in 2003 in Canada, Zymeworks evolved from a platform technology company into a clinical-stage oncology developer with partnerships involving major pharmaceutical companies and a growing internal pipeline.